Onconetix, Inc. 2025 Annual Report: Key Investor Takeaways

Summary of Key Points

• Ongoing Financial Distress and Going Concern Warning
• Pivotal Realbotix Transaction Could Transform the Company
• Continued Nasdaq Listing at Risk and Recent Compliance Actions
• Proclarix Commercialization is Central, But Revenues Remain Minimal
• ENTADFI Commercialization Abandoned
• Significant Potential for Shareholder Dilution

Detailed Analysis for Investors

Financial Position and Going Concern Issues

Onconetix, Inc. (Nasdaq: ONCO) faces severe financial challenges as it continues to post substantial operating losses, with an accumulated deficit of approximately \$131.2 million as of December 31, 2025. The company reported just \$5.2 million in cash at year-end, and a working capital deficit of \$3.1 million. As of March 11, 2026, cash was down to \$3.6 million. Management explicitly warns that current cash is not sufficient to fund operations for one year, raising serious doubt about the company’s ability to continue as a going concern. If additional capital is not secured, Onconetix may be forced to significantly curtail operations or cease altogether. Shareholders should consider the risk that their investment could be lost if the company cannot raise funds or generate revenues quickly.

Nasdaq Listing at Risk: Recent Compliance Developments

In early 2025, Onconetix received multiple deficiency notices from Nasdaq due to a closing bid price below \$1.00 and late filings of required reports. At one point, the stock traded below \$0.10 for ten consecutive days, triggering a risk of delisting. After a hearing, Nasdaq granted Onconetix a brief reprieve, contingent on regaining and maintaining compliance by June 30, 2025. The company responded with a 1-for-85 reverse stock split and timely filings to restore compliance. Nasdaq notified Onconetix on July 7, 2025, that it had regained compliance. However, management cautions that ongoing compliance is not assured—failure to maintain listing requirements could result in the loss of Nasdaq trading status, which would be highly detrimental to share value and liquidity.

Strategic Transaction: Realbotix Share Exchange Agreement

Onconetix has entered into a transformative Share Exchange Agreement with Realbotix, LLC. The deal structure means Realbotix will receive a substantial ownership stake in Onconetix post-transaction, potentially up to 90% of the fully diluted shares if Onconetix’s net cash at closing is less than \$15 million. The percentage drops to 85%, 80%, or 75% depending on higher net cash balances, but in every case, existing shareholders face massive dilution. The transaction is subject to various closing conditions, including the delivery of audited Realbotix financial statements and shareholder approval. Termination fees of up to \$2 million may apply under certain circumstances. There are strict covenants on both companies’ operations between signing and closing, plus lock-up and non-compete agreements for key stakeholders.

This transaction will fundamentally reshape the company—investors should understand that post-transaction, control will shift to Realbotix stakeholders and existing shareholders will own a much smaller percentage of the company.

Business Focus: Proclarix and Commercialization Strategy

Onconetix is now a commercial-stage biotechnology company focused on men’s health and oncology, with its primary product being Proclarix, a diagnostic tool for prostate cancer. The company’s future depends on successful commercialization of Proclarix, partnership with LabCorp for U.S. marketing, and integration of assets from the Proteomedix acquisition. However, revenue from this product remains minimal, and the company stresses that it is dependent on a single product. There is no guarantee of commercial success.

End of ENTADFI Commercialization

Onconetix abandoned commercialization of ENTADFI, a previously acquired asset, due to resource constraints and lack of inventory. The company terminated employees associated with the program and fully impaired related assets. There are currently no plans to resume the program.

Risks and Shareholder Impacts

• Ongoing Losses, Capital Constraints, and “Going Concern” Uncertainty: The company’s survival hinges on raising substantial new capital, the success of Proclarix, and the Realbotix transaction. If unsuccessful, shareholders could lose their entire investment.
• Major Shareholder Dilution: The Realbotix transaction will result in significant dilution for existing shareholders, with new Realbotix owners potentially controlling up to 90% of the company.
• Nasdaq Delisting Risk: Repeated compliance failures mean the company remains at risk of being delisted, which would severely impact stock liquidity and value.
• Control Shifts and Governance Changes: The transaction includes lock-ups, non-competes, and board changes, fundamentally altering governance.
• Uncertain Commercial Outlook: With only one product (Proclarix), the company’s future revenue stream is highly uncertain.
• Intellectual Property, Legal, and Regulatory Risks: The company faces risks related to IP protection, regulatory compliance, and potential legal liabilities.

Conclusion: Why This is Price-Sensitive

The combination of an existential cash crisis, risk of Nasdaq delisting, and the Realbotix transaction—which will massively dilute current shareholders and shift control—makes this report highly price-sensitive. Investors should be aware that Onconetix is at a critical crossroads: survival depends on raising capital and closing the Realbotix deal, but both come at the cost of control and potential further dilution. Any developments around these issues could drive significant share price movement, up or down.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult a qualified financial advisor before making investment decisions. The information is based on the company’s public filings and may be subject to change without notice. Investing in securities involves risk, including the risk of loss.

View Onconetix, Inc. Historical chart here